TickerFacts.

Atara Biotherapeutics, Inc. (ATRA): Revenue

Annual figures by period end, from SEC filings.

$120.77M
Year ended 2025-12-31
$6.19M
Trailing 12 months to 2026-06-30
+23.9%
3-year compound annual growth
$128.94M2022-12-31: $63.57M2023-12-31: $8.57M2024-12-31: $128.94M2025-12-31: $120.77M$120.77M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$120.77M-6.3%2026-03-16, From 2025-01-01
2024-12-31$128.94Mn/m2026-03-16, From 2024-01-01
2023-12-31$8.57M-86.5%2025-03-07, From 2023-01-01
2022-12-31$63.57Mn/a2024-03-28, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$120.77M-6.3%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$123.67M+63.5%
Agenus Inc (AGEN)2025-12-31$114.20M+10.4%
ImmunityBio, Inc. (IBRX)2025-12-31$113.29M+668.3%
Century Therapeutics, Inc. (IPSC)2025-12-31$109.16Mn/m
Beam Therapeutics Inc. (BEAM)2025-12-31$139.74M+120.0%
Sutro Biopharma, Inc. (STRO)2025-12-31$102.48M+65.2%
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31$170.16M-25.1%
REGENXBIO Inc. (RGNX)2025-12-31$170.44M+104.5%

Compare ATRA, GLUE, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗